Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa
International Journal of Dermatology · 2023
DOI: 10.1111/ijd.16752 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Dermatology, 2023. Verfasst von Lei Shao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: Science and Technology General guidance project of Guangzhou Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China.
- Institute of Dermatology, Guangzhou Medical University, Guangzhou, China.
Förderung
- Science and Technology General guidance project of Guangzhou Health
Zitieren
APA
Shao, L., Zhong, D. Q., Liu, Y. M., & Wang, J. Q. (2023). Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa. International Journal of Dermatology. https://doi.org/10.1111/ijd.16752
Vancouver
Shao L, Zhong DQ, Liu YM, Wang JQ. Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa. International Journal of Dermatology. 2023. doi:10.1111/ijd.16752
BibTeX
@article{Shao2023,
author = {Shao, Lei and Zhong, Dao-Qing and Liu, Yu-Mei and Wang, Jian-Qin},
title = {Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa},
journal = {International Journal of Dermatology},
year = {2023},
doi = {10.1111/ijd.16752}
}
EUVIMED